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Abstract
Background. The status of the cardiovascular (CV) system in children with chronic kidney disease (CKD) 
is significantly influenced by increasing stiffness of the arterial wall. This largely depends on the shortage 
of local and systemic inhibitors of soft tissue calcification.
Objectives. The aim of the study was to evaluate the role of fetuin-A in conjunction with other factors 
in the progressive hardening of the vascular wall in these children. We examined serum fetuin-A concentra-
tions in relation to renal function, dialysis modality, and other clinical and biochemical markers promoting 
vascular calcification.
Material and methods. Twenty children on peritoneal dialysis (PD), 20 on hemodialysis (HD), 36 treated 
conservatively, and 26 healthy subjects were enrolled into a cross-sectional study. In all children, fetuin-A 
and numerous clinical and biochemical parameters were measured.
Results. The fetuin-A concentration was significantly lower in children on hemodialysis (HD) vs children 
on peritoneal dialysis (PD), conservatively treated subjects, and the control group. In sick children, fetuin-A 
concentration negatively correlated with dialysis vintage, PWV/ht, phosphate concentration, calcium phos-
phate product (CaxP), cumulative doses of calcium, and vitamin D3. In the whole study population, fetuin-A 
negatively correlated with blood pressure (BP), pulse wave velocity indexed to height (PWV/ht), intact 
parathyroid hormone (iPTH), high sensitivity C-reactive protein (hsCRP), and cholesterol concentrations.
Conclusions. In children with CKD, the decreased concentration of fetuin-A is related to other vascular 
calcification risk factors. Serum fetuin-A concentration may play a role in the identification of vascular disease 
risk factors in this population.
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Introduction
The status of the cardiovascular (CV) system in chil-
dren with chronic kidney disease (CKD) depends largely 
on the growth in vessel wall stiffness (atherosclerosis). 
Mönckeberg-type medial calcification leads to an exac-
erbation of arterial stiffness, resulting in a rise in systolic 
blood pressure (SBP) and a reduction in diastolic blood 
pressure (DBP), as well as in an increase in pulse pressure 
value (PPV), which has been recognized as an indepen-
dent risk factor for death from CV causes.1 In the course 
of progressive stiffening of the vessel wall, left ventricu-
lar hypertrophy, impairment of coronary blood flow and 
calcification of the heart valves are observed. All of these 
disorders lead to increased risk of myocardial infarction, 
arrhythmia and heart failure, and consequently, to sudden 
death.2,3 In patients with CKD, additional risk factors are 
disturbed calcium metabolism, phosphate (P), high para-
thyroid hormone (PTH) level, elevated calcium phosphate 
product (CaxP), the number of episodes of hypercalcemia, 
and doses of calcium phosphate binders.4,5 The promoting 
factors of the formation of calcifications are long-lasting 
hypercalcemia and hyperphosphatemia, but the sever-
ity of changes largely depends on genetic predisposition. 
Block et al. reported on the negative correlation between 
the degree of calcification of the vascular wall and bone 
turnover.6 Similarly, other authors have shown that pa-
tients on dialysis who have had low levels of intact PTH 
(iPTH) and low alkaline phosphatase activity, the degree 
of calcification increases faster than in patients with high 
levels of iPTH.4 In light of recent reports, it is considered 
that the calcification of blood vessels is an active process 
that is initiated by hyperphosphatemia and is associated 
with deficient endogenous inhibitors of calcification.7,8 
The basic structure responsible for this process is vascular 
smooth muscle cells (VSMC). Chronic kidney disease pa-
tients, especially patients on chronic dialysis, are deficient 
in systemic and local soft tissue calcification inhibitors.
The greatest interest of researchers is currently focused 
on  fetuin-A (α2-Heremans-Schmid-glycoprotein), the 
main systemic inhibitor of calcification in soft tissues. 
Synthesized in the liver, it reaches a high concentration 
in extracellular fluid, including plasma (above 1 g/L). Fe-
tuin-A shows a negative relationship with inflammatory 
markers. The results of experimental studies demonstrate 
its important role in the inhibition of vascular wall calci-
fication. It has been shown that mice lacking the gene for 
fetuin-A have severe metastatic calcifications of the soft 
tissues.9 The action of fetuin-A is performed through the 
binding of small calcium phosphate crystals, thus inhibit-
ing their growth and deposition in tissues. It was found that 
in the presence of fetuin-A, a soluble complex called cal-
cyprotein is formed, comprised of 8 molecules of fetuin-A 
(80% of the complex by weight), 1 molecule of matrix Gla 
protein (MGP) (2% by weight), 790 atoms of calcium, and 
580 molecules of phosphate (18% by weight).10 The fetuin-A 
is able to inhibit the activity of TGF-β and macrophages, 
and thereby to reduce the release of proinflammatory cy-
tokines.11 In the presence of calcium, it has an affinity for 
proteins located on the cell surface – annexin II and VI. Fe-
tuin-A binds to them and enters the endosomes of smooth 
muscle cells, thus inhibiting their apoptosis. The fetuin-A 
entering into the matrix vesicles and apoptotic bodies pre-
vents soft tissue mineralization. It has also been found that 
fetuin-A accelerates the phagocytosis of apoptotic bod-
ies and inhibits VSMC function and bone morphogenetic 
protein 2 function.12,13 Many investigators have shown that 
in patients with CKD, especially stage 5, fetuin-A is sig-
nificantly lower than in healthy individuals, which can 
affect the increased mortality from CV disease in these 
patients.14–17 Goodman et  al. have studied this aspect 
of young adults (20–30 years of age) undergoing chronic 
hemodialysis (HD). Almost all patients (88%) presented 
calcifications in the coronary arteries, especially those 
who started dialysis early in childhood.4 There have been 
only single reports of vascular calcification in children and 
adolescents with CKD.14,18–21
The aim of the study was to assess serum fetuin-A con-
centrations in children with CKD in relation to renal func-
tion, dialysis modality, and other clinical and biochemical 
markers promoting vascular calcification.
Material and methods
Seventy-six children with CKD, still asymptomatic of CV 
complications, were enrolled into the study. The patients 
were divided into 3 groups according to CKD stage and 
dialysis modality. Twenty-six age-matched children with 
primary nocturnal enuresis and normal kidney function 
served as controls. Clinical and demographic details of the 
study subjects are summarized in Table 1. The 1st group 
included 20 children on peritoneal dialysis (PD). Nocturnal 
intermittent peritoneal dialysis (NIPD) was performed 
in 12 patients and continuous cyclic peritoneal dialysis 
(CCPD) was administered in 8 patients. A Home-Choice 
machine was used (Baxter International, Inc., Deerfield, 
USA). Standard dialysis solutions with glucose concen-
trations of 1.5% and 2.3% and calcium concentrations 
of  1.25  mmol/L or 1.75  mmol/L were applied accord-
ing to individual recommendations. The causes of CKD 
in children from the 1st group (PD group) included struc-
tural urinary tract abnormalities (n = 9), glomerulonephri-
tis (n = 5), polycystic kidney disease (n = 3), hereditary ne-
phropathy (n = 2), and hemolytic uremic syndrome (n = 1). 
Fifteen children remained on hypotensive medication, in-
cluding angiotensin-converting enzyme inhibitors (ACEI) 
(n = 13), calcium channel blockers (n = 6) and β-blockers 
(n = 3). All of the subjects received calcium-containing 
phosphate binders and vitamin D metabolites in doses 
adjusted to their requirements.
The  2nd group (HD group) consisted of  20  children 
on maintenance HD. Dialysis sessions were performed 
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3  times a  week (3–5  h) using polysulfone membranes. 
The blood flow ranged from 120 to 250 mL/min, and di-
alysate flow did not exceed 500 mL/min. The dialysis fluid 
was buffered with bicarbonate and the calcium content was 
1.25 mmol/L or 1.5 mmol/L. The causes of CKD in this 
group were urinary tract abnormalities (CAKUT) (n = 12), 
glomerulonephritis (n = 6) and hereditary glomerulopa-
thy (n = 2). Nineteen hypertensive children were treated 
with ACEi (n = 19), calcium channel blockers (n = 11) and 
β-blockers (n = 2). All of the patients received calcium-
containing phosphate binders and vitamin D compounds.
The 3rd group (Pre group) included 36 children with CKD 
(stages 2–4) on conservative treatment. The causes of CKD 
were urinary tract malformations (n = 22), glomerulone-
phritis (n = 5), polycystic kidney disease (n = 3), hereditary 
glomerulopathy (n = 2), unknown cause (n = 2), hemolytic 
uremic syndrome (n = 1), and complications after che-
motherapy for cancer (n = 1). Stage 2 CKD was detected 
in 13 children, stage 3 in 10 and stage 4 in 13. Twelve sub-
jects were treated with ACE-I, 6 patients with angiotensin 
receptor blockers (ARB), 4 patients with calcium channel 
blockers, and 1 child received β-blockers.
All patients with stage 3 or 4 CKD as well as 5 children 
with stage 2 CKD received treatment with calcium-con-
taining phosphate binders and vitamin D compounds.
Children under the age of 6 years and patients with dia-
betes or infection were excluded from the study. Informed 
consent for participation in the study was obtained from 
all of the parents and from children 15 years old or older. 
The research project was approved by the Wroclaw Medi-
cal University (Poland) ethics committee.
Selected biochemical and functional parameters in the 
study population were measured in order to assess the de-
gree of vascular stiffness. In all patients and in the control 
group, the following biochemical parameters were deter-
mined: serum creatinine, albumin, acute phase proteins 
(high sensitivity C-reactive protein (hsCRP)), hemoglobin 
(Hb), lipid count (total cholesterol (TCL), low-density li-
poproteins cholesterol (LDL-cholesterol), high-density 
lipoproteins cholesterol (HGL-cholesterol), and triglyc-
erides (TGL)), as well as parameters related to calcium P 
metabolism (calcium, P and iPTH). The serum concentra-
tion of fetuin-A was also measured as a principal systemic 
inhibitor of soft tissue calcification.
As part of the assessment of vascular function, 24-h blood 
pressure (BP) was monitored with the evaluation of SBP, 
DBP, mean blood pressure (MBP), pulse pressure (PP), 
and pulse wave velocity (PWV).
The stage of CKD was diagnosed based on the The Na-
tional Kidney Foundation Kidney Disease Outcomes Qual-
ity (NKFK/DOQI) recommendations and the calculation 
of glomerular filtration rate (GFR) was performed using 
the Schwartz formula.22
In dialysis patients, the type and duration of renal re-
placement therapy was taken into account. In each patient, 
based on the measurement of height and weight, body mass 
index (BMI) was determined according to this formula: 
BMI = body weight [kg]/height [m2].
Blood pressure was measured using a sphygmomanom-
eter or an electronic DIANA device (DINAMAP, Boston, 
USA) for 24-hour monitoring. Measurements were taken 
in a seated position with the appropriate cuff selected 
to cover the width of 1/3 of the length of the arm. Normal 
BP values were defined as values below the 90th percentile 
and below the upper BP limit (according to the nomencla-
ture defined in the Fourth Report on the Diagnosis, Evalu-
ation, and Treatment of High Blood Pressure in Children 
and Adolescents) and prehypertension was defined as val-
ues between the 90th and the 95th percentile.23 For the eval-
uation of the results, percentile charts relating to gender, 
age and growth percentile from the National High Blood 
Pressure Education Program Working Group on High 
Blood Pressure in Children and Adolescents, Third Re-
port, were used.24 The percentile growth charts we used 
Table 1. Clinical characteristics of the chronic kidney disease (CKD) groups and the controls (two-by-two comparison, p-values are shown)
Group
parameter
PD
n = 20
HD
n = 20
Pre
n = 36
Controls
n = 26 p-value
Age [year] 14.3 ±2.3 15 ±3.3 14.9 ±3.5 14.5 ±3.3 NS
Gender [male/female] 12/8 10/10 17/19 12/14 NS
Dialysis vintage [months] 12 ±11 19 ±16 – – p = 0.02
BMI [kg/m2] 18.7 ±3.9 18.7 ±3.4 20.6 ±4.1 18.8 ±3.9 NS
SBP [mm Hg] 117 ±111,3 128 ±131,2,4 115 ±101 100 ±9 p < 0.0001
DBP [mm Hg] 75 ±111,3 82 ±101,2,4 71 ±81 64 ±6 p < 0.0001
PP [mm Hg] 42 ±91 46 ±91 44 ±81 35 ±7 p < 0.0001
MBP [mm Hg] 86 ±121,3 97 ±101,2,4 86 ±71,3 76 ±6 p < 0.0001
Cumulative dose of calcium [g/kg] 29.7 ±45.9 46.6 ±45.84 9.67 ±12.53 – p = 0.0002
Cumulative dose of vitamin D3 [μg/kg] 3.71 ±3.7 4.76 ±3.374 2.02 ±4.413 – p = 0.0005
PWV/ht [m/s] 5.51 ±0.681,3 6.07 ±0.861,2,4 5.53 ±0.691,3 4.85 ±0.62 p < 0.0001
PD – peritoneal dialysis; HD – hemodialysis; Pre – predialysis; BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure;  
PP – pulse pressure; MBP – mean blood pressure; PWV/ht – pulse wave velocity indexed to height; NS – not significant.
1 vs control group; 2 vs PD group; 3 vs HD group; 4 vs Pre group.
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in our study were developed by the Institute of Mother and 
Child in Warszawa, Poland. Mean blood pressure and PP 
were calculated according to these formulas: MBP = DBP 
+ [(SBP – DBP)/3] and PP = SBP – DBP. In each patient, 
the cumulative dose of oral calcium in the gastrointesti-
nal tract, mostly taken in the form of calcium-containing 
phosphate binders, was calculated. The cumulative dose 
of the active form of vitamin D3 which each patient had 
previously received was also calculated.
Blood samples were collected in the morning, under fast-
ing conditions, while performing other routine tests. In or-
der to determine the concentration of creatinine, albumin, 
Hb, acute phase protein (hsCRP), TCL, LDL-cholesterol, 
HDL-cholesterol, TGL, calcium, and phosphate, blood was 
simultaneously drawn and the serum parameters were as-
sayed on the same day. For fetuin-A, blood was drawn into 
dry tubes, then centrifuged at 3,000 rpm for 15 min and the 
serum was frozen at –20°C until assayed. The blood used 
in iPTH testing was collected into tubes containing eth-
ylenediaminetetraacetic acid (EDTA) and centrifuged for 
15 min at 1,000 rpm, within 30 min of sampling. After the 
separation of plasma from cellular components, the plasma 
was frozen and stored at –20°C until assayed. Serum creati-
nine, albumin, calcium, phosphate, lipid, and hsCRP levels, 
as well as a complete blood count, were assessed in Cen-
tral Laboratory, University Teaching Hospital in Wrocław, 
Poland, with standard methods. The iPTH concentration 
was determined by IRMA using Duo PTH manual kits 
(Scantibodies Laboratory, Inc., Santee, USA) (standard 
laboratory normal value: 14–66 pg/mL). The measurement 
of fetuin-A was performed twice and the mean values were 
analyzed. Fetuin-A was determined by enzyme-linked im-
munosorbent assay (ELISA) using a commercially available 
kit (BioVendor, Brno-Řečkovice a Mokrá Hora, Czech Re-
public). The PWV study was performed according to the 
methodology we presented in an earlier work.25
Statistical analyses were performed using the STAT-
GRAPHICS package (Centurion XV v. 15.2.06, StatPoint, 
Inc. Herndon, USA). The results were expressed as mean 
values ± standard deviation (SD) when a normal distri-
bution of variables was obtained. The differences were 
then compared by an analysis of variance (ANOVA) test. 
In the case of non-normal distribution, a nonparametric 
Kruskal-Wallis test for median values was used. For the 
evaluation of the relationship between parameters with 
a normal distribution of variables, Pearson’s correlation 
test was performed. Spearman’s test was applied for data 
with non-normal distribution. Since the p-value in the 
ANOVA table was less than 0.05, there was a statistically 
significant relationship between the variables. A p-value 
of less than 0.05 in other tests was considered statistically 
significant.
Results
The study groups were not found to differ significantly 
with respect to age, sex or BMI. The concentration of fe-
tuin-A was the lowest in the HD group and was signifi-
cantly different from the concentrations of the PD group, 
the Pre group and the group of healthy subjects. In patients 
undergoing PD, fetuin-A concentration was significantly 
lower than in Pre group patients and in the healthy con-
trols. The highest values of this calcification inhibitor were 
detected in the control group. Detailed data are shown 
in Table 2.
The highest BP, SBP, DBP, and MBP values were found 
in the group of children on HD. They varied significantly 
compared to the group of healthy children, to the PD group 
and to the Pre group. Pulse pressure was significantly 
higher in all groups of children with CKD in comparison 
to healthy peers, regardless of the stage of the disease or 
the methods of renal replacement therapy. The duration 
of PD was shorter than the time of chronic HD treatment. 
Children in the HD group received the highest cumulative 
dose (per kg of body weight) of both calcium carbonate and 
active metabolites of vitamin D3. The difference was statis-
tically significant in comparison to the children in the Pre 
group. The highest values of PWV/ht were noted in HD 
patients, and they differed significantly from the results 
obtained in all other groups. Pulse wave velocity indexed 
to height (PWV/ht) measurements were also significantly 
higher in the PD group and in the Pre group than in the 
control group. Detailed data are presented in Table 1.
Significantly lower albumin concentration and higher to-
tal cholesterol and triglyceride levels were observed in PD 
and Pre groups than in healthy controls. The highest con-
centration of LDL-cholesterol and total cholesterol, found 
in the PD group, differed significantly from the values 
recorded in other groups. In all CKD groups, Hb levels 
were lower than in the healthy subjects. The most pro-
nounced decrease in Hb concentration was observed 
in the HD group. The lowest concentration of calcium 
and the highest of  phosphate were found in  the HD 
group. These values were significantly different from 
the other groups.
Table 2. Fetuin-A concentration in the study groups (two-by-two comparison, p-values are shown)
Group
parameter
PD
n = 20
HD
n = 20
Pre
n = 36
Control
n = 26 p-value
Fetuin-A [ng/mL] 56.67 ±0.551,3,4 40.73 ±0.961,2,4 63.38 ±0.881,2,3 98.56 ±0.95 p < 0.0001
PD – peritoneal dialysis; HD – hemodialysis; Pre – predialysis.
1 vs control group; 2 vs PD group; 3 vs HD group; 4 vs Pre group.
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The values of CaxP in children with CKD on dialysis treat-
ment were significantly higher than in the control group 
and in patients treated conservatively (Pre group), but did 
not differ regarding dialysis modality. The highest values 
of iPTH levels were found in the HD group; they differed 
significantly in relation to other groups. The CRP concen-
tration was also highest in the HD group and was signifi-
cantly different from those observed in the control group 
and the PD group. There were no significant differences 
in CRP levels between the Pre group and the control group 
or the PD group. Detailed data is shown in Table 3. In the 
total population of children with CKD (PD + HD + Pre), 
we found statistically significant negative linear correla-
tions of fetuin-A levels with PWV/ht, dialysis duration, P, 
CaxP, and the cumulative doses of calcium and vitamin D3. 
Detailed data is presented in Table 4.
In the entire study population, we observed similar cor-
relations regarding fetuin-A among all patients. In addition 
in the whole analyzed population, we found a negative 
linear correlation between fetuin-A and blood pressure 
values (SBP, DBP, PP, and MBP), iPTH, hsCRP, total 
Table 3. Biochemical characteristics of the chronic kidney disease (CKD) groups and the controls (two-by-two comparison, p-values are shown)
Group
parameter
PD
n = 20
HD
n = 20
Pre
n = 36
Controls
n = 26 p-value
Hb [g/dL] 11.14 ±1.231 10.19 ±1.341,4 11.99 ±2.071,3 13.3 ±1.19 p < 0.0001
Albumin [g/dL]    3.9 ±0.341    4.0 ±0.35     3.9 ±0.681   4.3 ±0.44 p = 0.009
Total cholesterol [mg/dL]   206 ±431   174 ±33    203 ±1001  162 ±13 p = 0.0001
LDL-cholesterol [mg/dL]   143 ±441,3,4     92 ±312    105 ±692    84 ±6.2 p < 0.0001
HDL-cholesterol [mg/dL]     52 ±15     46 ±9      50 ±10    49 ±4 NS
TGL [mg/dL]   179 ±751   166 ±59    187 ±2421    86 ±6.5 p < 0.0001
Calcium [mg/dL]  9.71 ±0.793  9.23 ±0.561,2,4   9.69 ±0.631,3 9.99 ±0.34 p = 0.0002
P [mg/dL]  5.48 ±1.811,3,4  6.32 ±1.171,2,4   4.52 ±0.972,3 4.45 ±0.54 p < 0.0001
Ca × P [mg2/dL2]  53.5 ±19.41,4  58.1 ±101,4   43.6 ±8.92,3 44.3 ±5.3 p < 0.0001
iPTH [pg/mL]   206 ±1771,3  444 ±5241,2,4    138 ±1353 30.7 ±4 p < 0.0001
hsCRP [mg/L]  2.97 ±0.453 3.64 ±0.981,2     3.3 ±0.65   2.5 ±0.15 p < 0.0001
Creatinine [mg/dL]  6.37 ±2.61,4    7.6 ±3.41,4     2.5 ±1.61,2,3 0.68 ±0.11 p < 0.0001
PD – peritoneal dialysis; HD – hemodialysis; Pre – predialysis; TCL – total cholesterol; LDL-cholesterol – low-density lipoproteins cholesterol; HDL-cholesterol 
– high-density lipoproteins cholesterol; TGL –  triglycerides; P – phosphate; CaxP – calcium phosphate product; iPTH – intact parathormone; hsCRP – high 
sensitivity C-reactive protein; NS – not significant.
1 vs control group; 2 vs PD group; 3 vs HD group; 4 vs Pre group.
Table 4. Analyses of factors correlated with fetuin-A in CKD patients (PD + 
HD + Pre) (Pearson correlation test)
Variable r p-value
Fetuin-A dialysis vintage r = –0.34 p = 0.002
P r = –0.23 p = 0.03
CaxP r = –0.27 p = 0.01
Cumulative dose of calcium r = –0.22 p = 0.04
Cumulative dose of vitamin D3 r = –0.26 p = 0.02
PWV/ht r = –0.47 p < 0.0001
P – phosphate; CaxP – calcium phosphate product; PWV/ht – pulse wave 
velocity indexed to height; r – correlation coefficient.
Table 5. Analyses of factors correlated with fetuin-A in the whole study 
population (Pearson correlation test)
Variable r p-value
Fetuin-A SBP r = –0.53 p < 0.0001
DBP r = –0.44 p < 0.0001
PP r = –0.33 p = 0.0006
MBP r = –0.44 p < 0.0001
P r = –0.32 p = 0.0009
Ca r = 0.24 p = 0.01
CaxP r = –0.28 p = 0.003
iPTH r = –0.31 p = 0.001
Cumulative dose of calcium r = –0.35 p = 0.0002
Cumulative dose of vitamin D3 r = –0.41 p < 0.0001
Total cholesterol r = –0.21 p = 0.03
LDL-cholesterol r = –0.22 p = 0.02
TGL r = –0.23 p = 0.01
hsCRP r = –0.32 p = 0.0009
PWV/ht r = –0.39 p < 0.0001
SBP – systolic blood pressure; DBP – diastolic blood pressure; PP – pulse 
pressure; MBP – mean blood pressure; P – phosphate; CaxP – calcium 
phosphate product; iPTH – intact parathormone; LDL – low-density 
lipoproteins cholesterol; TGL – triglycerides; hsCRP – high sensitivity 
C-reactive protein; PWV/ht - pulse wave velocity indexed to height.
cholesterol, LDL-cholesterol, and TGL. Detailed data is 
presented in Table 5. In the control group, there were no 
statistically significant correlations with fetuin-A. Assess-
ing the impact of a single HD session on serum fetuin-A 
concentration, a significant increase in the concentra-
tion of  fetuin-A after HD was found. Detailed data is 
presented in Table 6.
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Discussion
The  complex pathogenesis of  vascular injury in  the 
course of CKD also involves factors that promote and 
inhibit calcification of soft tissues. While the influence 
of stimulating factors such as calcium, P, PTH, vitamin D3, 
and calcium phosphate-binding formulas on this process 
is well-known, less has been documented about the role 
of calcification inhibitors. Fetuin-A, which creates about 
50% of the total plasma pool of calcification-inhibiting 
compounds, has been the subject of interest in patients 
with CKD over the past few years. In this study, the con-
centration of fetuin-A was significantly lower in all exam-
ined children with CKD compared to the control group, 
but the biggest decrease was observed in HD group. This 
is consistent with the vast number of reports on the subject 
in adults.15,16,26,27 The explanation for the reduced levels 
of fetuin-A may be the status of chronic inflammation, 
which in patients with end-stage renal failure is the most 
severe causative factor.
The influence of  inflammation on the concentration 
of serum fetuin-A is supported by the research of Dervi-
soglu et al., who showed a negative correlation between 
fetuin-A and the concentration of proinflammatory cyto-
kines.28 In a group of adults on HD, a relationship was also 
found between low levels of fetuin-A and higher mortality 
from CV causes. On the other hand, Shroff et al. presented 
different results in children: an increase in circulating lev-
els of fetuin-A in children undergoing dialysis compared 
to healthy peers.29 Lower concentrations of fetuin-A were 
observed only in patients with heart valve and coronary 
artery calcifications. But even in these cases, concentra-
tions of fetuin-A were higher than those observed in the 
control group. Nevertheless, it should be noted that the 
average time on dialysis was nearly half as long in their 
study as in our population, which is probably not without 
significance.
Additionally, a negative correlation between serum fe-
tuin-A and dialysis duration has also been demonstrated 
by other authors. According to Shroff et al., elevated levels 
of fetuin-A in children undergoing dialysis could be re-
garded as an initial phase of a systemic response to pro-
inflammatory and hypercalcemic agents. The authors sug-
gest that a prolonged stimulation of such factors can reduce 
the compensation mechanisms of the body and can lead 
to a reduction in the concentration of natural inhibitors 
of calcification.29 On the other hand, Ziółkowska et al.
examined 28 children on dialysis (either on HD or PD) and 
43 healthy children, and found no significant difference 
in the concentration of fetuin-A between the 2 groups.30
The results of research on the levels of fetuin-A in PD 
patients are also ambiguous: different authors found both 
higher levels and the same levels in comparison to adult 
patients on HD.31,32 In our study population, we demon-
strated significantly lower concentrations of this calcifica-
tion inhibitor in children on PD than in patients treated 
conservatively. However, compared to children on HD, the 
values were significantly higher. This can be explained not 
only by the shorter dialysis duration, but also by the less 
severe disorders of calcium-phosphate metabolism com-
pared to children on HD. The negative correlation between 
the concentration of phosphate, CaxP, iPTH, and fetuin-A 
in the group of all patients with CKD seems to confirm this 
hypothesis. In children treated conservatively, fetuin-A 
level was the highest, although it was still lower than in the 
control group. These results do not support the observa-
tions made by Schaible et al., who did not show such dif-
ferences.14 In one of the few studies on pediatric kidney 
transplantation, Van Summerenet al.32 found a significant 
decrease in the concentration of fetuin-A, in contrast to the 
observations of Schaible et al.14 It should be emphasized 
that the reports on predialysis patients and PD are limited 
and include heterogeneous groups regarding the amount 
of procalcemic factors, chronic inflammation and comor-
bid conditions, which partly explains these differences. 
Also, one cannot rule out genetic factors which, as shown 
by studies of the German authors, may individually affect 
the synthesis of these inhibitors.33 Also, it is important that 
fetuin-A is not only an inhibitor of calcification, but that 
it also plays other roles within the body. It acts as a nega-
tive acute phase protein which inhibits the overproduction 
of proinflammatory cytokines and modulates the activity 
of the insulin receptor, affecting insulin resistance.34
Regardless of these discrepancies, there is much evidence 
that fetuin-A plays a protective role against vascular calcifi-
cation and increasing vascular stiffness. This is confirmed 
by both studies in animal models and by clinical data in pa-
tients with CKD, showing a negative correlation between 
fetuin-A concentration and the presence of calcifications 
in the coronary arteries, carotid artery intima-media thick-
ness, and pulse wave acceleration.35–40 Fetuin-A proved 
to also be an independent predictor of stiffness and vascu-
lar calcification in children after renal transplantation.33 
In our study, we demonstrated a significant negative corre-
lation between serum fetuin-A and the values of PWV/ht, 
BP, calcium, and lipid metabolism. Ziółkowska et  al. 
studied the influence of many factors responsible for the 
progression of blood vessel calcification – including indices 
of calcium and P metabolism, degree of bone turnover, 
and lipids in children at different stages of CKD, with and 
without vascular changes – and revealed that only fetuin-A 
was the differentiating factor.30
Our study has several limitations. Firstly, the sample 
size, particularly subgroups, may be insufficient to show 
Table 6. The impact of a single hemodialysis (HD) session on serum 
fetuin-A concentration
Serum Before HD After HD p-value
Fetuin-A
[ng/mL]
40.73 ±0.96 52.41 ±0.58 p < 0.0001
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significant differences. Our patients were recruited from 
3 of the pediatric nephrology centers which treat children 
from the whole southern region of Poland. Further studies 
with larger sample sizes are necessary, especially in light 
of new therapeutic methods which enable the lowering 
of vascular stiffness in CKD pediatric patients.
It can be concluded that the reduced serum fetuin-A 
concentration which is particularly pronounced in dia-
lyzed children and its relationship with other progressive 
arterial stiffness risk factors indicate a significant role 
of this calcification inhibitor in the development of CV 
complications in children with CKD.
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